Fast Five Quiz: Heart Failure With Reduced Ejection Fraction (HFrEF) Treatment Optimization

Alanna Morris, MD; Michael Weber, MD; Jeffrey J. Hsu, MD


March 13, 2023

SGLT2 inhibitors are recommended by the AHA/ACC/HFSA for patients with symptomatic chronic HFrEF, irrespective of the presence of type 2 diabetes. In two clinical trials, the addition of the SGLT2 inhibitors dapagliflozin and empagliflozin to standard therapies for patients with HFrEF resulted in a consistent ~25% relative risk reduction of the primary endpoint of cardiovascular death or hospitalization for heart failure.

SGLT2 inhibitors have also been shown to improve renal outcomes in patients with HFrEF. In trials of empagliflozin and dapagliflozin, no patients without diabetes developed ketoacidosis, although SGLT2 inhibitors do increase the risk for diabetic ketoacidosis in patients with diabetes and other high-risk conditions.

Learn more about the treatment of HFrEF.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.